---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-107409"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2022-10-11T23:59:59+00:00"
generated_at: "2026-06-23T04:15:10.596236+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics enrolls first patient in Phase 3 TETON 2 study of Tyvaso for IPF

## Summary
- First patient enrolled in Phase 3 TETON 2 study of Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).
- Study targets 396 adult IPF patients at sites outside the US and Canada; 52-week treatment evaluating forced vital capacity (FVC).
- Tyvaso is already FDA-approved for PH-ILD but not for IPF without documented pulmonary hypertension.
- TETON program builds on positive FVC impact observed in the INCREASE study of inhaled treprostinil in IPF patients with PH.

## SEC filing metadata
- accession: 0001104659-22-107409
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2022-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465922107409/0001104659-22-107409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465922107409/tm2227915d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-107409
- JSON: https://secwatch.observer/filing/0001104659-22-107409.json
- Plain text: https://secwatch.observer/filing/0001104659-22-107409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.